Abstract:Importance: Depressive severity is typically measured according to total scores on questionnaires that include a diverse range of symptoms despite convincing evidence that depression is not a unitary construct. When evaluated according to aggregate measurements, treatment efficacy is generally modest and differences in efficacy between antidepressant therapies are small. Objectives: To determine the efficacy of antidepressant treatments on empirically defined groups of symptoms and examine the replicability of these groups. Design, setting, and participants: Patient-reported data on patients with depression from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial (n = 4039) were used to identify clusters of symptoms in a depressive symptom checklist. The findings were then replicated using the Combining Medications to Enhance Depression Outcomes (CO-MED) trial (n = 640). Mixed-effects regression analysis was then performed to determine whether observed symptom clusters have differential response trajectories using intent-to-treat data from both trials (n = 4706) along with 7 additional placebo and active-comparator phase 3 trials of duloxetine (n = 2515). Finally, outcomes for each cluster were estimated separately using machine-learning approaches. The study was conducted from October 28, 2014, to May 19, 2016. Main outcomes and measures: Twelve items from the self-reported Quick Inventory of Depressive Symptomatology (QIDS-SR) scale and 14 items from the clinician-rated Hamilton Depression (HAM-D) rating scale. Higher scores on the measures indicate greater severity of the symptoms. Results: Of the 4706 patients included in the first analysis, 1722 (36.6%) were male; mean (SD) age was 41.2 (13.3) years. Of the 2515 patients included in the second analysis, 855 (34.0%) were male; mean age was 42.65 (12.17) years. Three symptom clusters in the QIDS-SR scale were identified at baseline in STAR*D. This 3-cluster solution was replicated in CO-MED and was similar for the HAM-D scale. Antidepressants in general (8 of 9 treatments) were more effective for core emotional symptoms than for sleep or atypical symptoms. Differences in efficacy between drugs were often greater than the difference in efficacy between treatments and placebo. For example, high-dose duloxetine outperformed escitalopram in treating core emotional symptoms (effect size, 2.3 HAM-D points during 8 weeks, 95% CI, 1.6 to 3.1; P < .001), but escitalopram was not significantly different from placebo (effect size, 0.03 HAM-D points; 95% CI, -0.7 to 0.8; P = .94). Conclusions and relevance: Two common checklists used to measure depressive severity can produce statistically reliable clusters of symptoms. These clusters differ in their responsiveness to treatment both within and across different antidepressant medications. Selecting the best drug for a given cluster may have a bigger benefit than that gained by use of an active compound vs a placebo.

Symptom clustering of major depression in a national telehealth sample

Subphenotyping Depression Using Machine Learning and Electronic Health Records

Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach

Identifying data-driven subtypes of major depressive disorder with electronic health records

Dimensional and Categorical Solutions to Parsing Depression Heterogeneity in a Large Single-Site Sample

Data-driven Clustering Differentiates Subtypes of Major Depressive Disorder with Distinct Brain Connectivity and Symptom Features

Unique genetic and risk-factor profiles in clusters of major depressive disorder-related multimorbidity trajectories

Dissection of depression heterogeneity using proteomic clusters

Towards precision in the diagnostic profiling of patients: leveraging symptom dynamics as a clinical characterisation dimension in the assessment of major depressive disorder

Challenges in Using mHealth Data From Smartphones and Wearable Devices to Predict Depression Symptom Severity: Retrospective Analysis

Longitudinal Dynamics and Pluripotentiality of Polysymptomatic Clustering in Adolescent Mental Health.

Phenotypic distinctions in depression and anxiety: a comparative analysis of comorbid and isolated cases

Symptom clusters in adolescent depression and differential responses of clusters to pharmacologic treatment

Latent subtypes of depression in a community sample of older adults: Can depression clusters predict future depression trajectories?

Genetic heterogeneity and subtypes of major depression

Biotypes of Major Depressive Disorder Identified by a Multiview Clustering Framework

Depressive Symptom Clusters and Their Relationships with Anxiety and Posttraumatic Stress Disorder Symptoms in Patients with Cancer: the Use of Latent Class Analysis.

Digital Phenotyping for Differential Diagnosis of Major Depressive Episode: Narrative Review

Identifying latent subtypes of symptom trajectories in major depressive disorder patients and their predictors

Heterogeneity in Antidepressant Treatment and Major Depressive Disorder Outcomes Among Clinicians